<DOC>
	<DOCNO>NCT00000763</DOCNO>
	<brief_summary>To assess toxicity determine MTD intravenous TNP-470 administer weekly patient AIDS-related Kaposi 's sarcoma . To assess pharmacokinetics tumor response drug . Since evidence show neovascularization important development Kaposi 's sarcoma , drug inhibit angiogenesis , TNP-470 , may benefit patient disease .</brief_summary>
	<brief_title>A Phase I Study TNP-470 Treatment AIDS-Associated Kaposi 's Sarcoma</brief_title>
	<detailed_description>Since evidence show neovascularization important development Kaposi 's sarcoma , drug inhibit angiogenesis , TNP-470 , may benefit patient disease . Patients enter 7 escalate dose level TNP-470 . ( PER AMENDMENT 9/3/96 : dose maximum level change . ) Four patient treat give dose level must receive least 4 week therapy escalation subsequent cohort proceeds . If 50 percent patient give dose level experience dose-limiting toxicity , previous dose define MTD additional two patient treat MTD . Patients receive treatment 12 week , follow 2 week rest , follow additional 12 week treatment . Patients follow 12 week post-treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>AIDS-Related Opportunistic Infections</mesh_term>
	<mesh_term>O- ( chloroacetylcarbamoyl ) fumagillol</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : AZT , ddI , ddC , d4T provide patient receive least 2 week therapy prior study entry . ( Combination ddI/ddC permit . ) MAI prophylaxis . Required patient CD4 count &lt; 200 cells/mm3 : Aerosolized pentamidine , trimethoprim/sulfamethoxazole , dapsone PCP prophylaxis . Patients must : HIV infection . Cutaneous Kaposi 's sarcoma . Life expectancy least 3 month . Consent parent guardian 18 year age . NOTE : This protocol consider suitable prison population . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Peripheral neuropathy ( grade 2 bad ) . Underlying severe lifethreatening infection bacterial , viral , fungal , protozoal pathogen . Known hypersensitivity TNP470 , fumagillin , know related compound . PER AMENDMENT 9/3/96 : Cataracts . Concurrent Medication : Excluded : Combination therapy ddI/ddC ( although drug may administer alone combination AZT ) . Anticonvulsive medication . Steroids . Antineoplastic drug . Interferons . Systemic topical antiKaposi 's sarcoma agent regimens . Suramin . Aspirin . Warfarin . Heparin ( include heparin flush ) . Nonsteroidal antiinflammatory drug . Investigational status drug . Patients follow prior condition exclude : History substantial noniatrogenic bleeding disorder . History tumor malignancy Kaposi 's sarcoma , exception completely resect basal cell skin carcinoma situ cervical carcinoma . History seizure within past 10 year . PER AMENDMENT 9/3/96 : History cataract . Prior Medication : Excluded within 4 week prior study entry : Steroids . Antineoplastic drug . Interferons . Systemic topical antiKaposi 's sarcoma agent regimens . Excluded within 6 month prior study entry : Suramin . Unwilling refrain unprotected sexual contact activity may result HIV reinfection .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antineoplastic Agents</keyword>
</DOC>